Fosphenytoin

CHEMBL1201336 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
362.3 g/mol
LogP
0.6
Phase
4

This prodrug is rapidly converted to phenytoin in the bloodstream and is used for rapid control of seizures, particularly status epilepticus, when intravenous treatment is needed. It has a better tolerability profile at the injection site compared to direct phenytoin injection.

Peso molecular

362,2700 g/mol

LogP

0,60

TPSA

116,00 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Mecanismo de acción

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O

InChI

InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23)

Molecular Formula

C16H15N2O6P

HBD / HBA

3 / 6

Enlaces Rotables

5

Átomos Pesados

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

This prodrug is rapidly converted to phenytoin in the bloodstream and is used for rapid control of seizures, particularly status epilepticus, when intravenous treatment is needed. It has a better tolerability profile at the injection site compared to direct phenytoin injection.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Fosphenytoin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201336. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 56339. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.